Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA
Diffuse large B cell (DLBCL)-like post-transplant lymphoproliferative disorder (PTLD) affects up to 10% of thoracic transplant recipients. Although 50% of PTLDs can be related to Epstein-Barr virus (EBV) infection, and high or increasing EBV viral load may precede EBV+ PTLD, preemptive monitoring of EBV titers does not reliably predict PTLD . Consequently, we assessed the utility of circulating tumor DNA (ctDNA), a promising biomarker for many cancers including DLBCL, for early detection of PTLD.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: J. Soo, J. Schroers-Martin, A. Garofalo, D. Kurtz, N. D'Emilio, H. Luikart, A. Alizadeh, K. Khush Tags: 5 Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Heart | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants